{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:13:15Z","timestamp":1783530795996,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Background: Obesity is a chronic, relapsing disease that often proves resistant to lifestyle measures alone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are reshaping treatment, yet prospective real-world data remain limited. Objective: To prospectively assess the effects of once-weekly Semaglutide on weight, body composition, and metabolic health in obesity. Methods: An exploratory observational study of 37 patients initiating Semaglutide (mean age 31 years; 11 children and adolescents; 22 females) was conducted. All met obesity criteria (baseline BMI 34.7 kg\/m2). Anthropometry, bioimpedance body composition, and fasting biochemistry were obtained at baseline and 3 months. Variables were reported as mean \u00b1 SD or median (IQR) according to normal\/non-normal distribution, whether a parametric test or a Wilcoxon one was used. Parametric or non-parametric paired tests (two-sided \u03b1 = 0.05) were applied. We also explored tri-ponderal mass index (TMI, kg\/m3) and its correlations with metabolic markers. Results: At 3 months, body weight decreased by a median 8.0 kg (p &lt; 0.001), BMI by 1.6 kg\/m2 (p &lt; 0.001). Body fat percentage declined: 43.4% to 42.8% (p = 0.009), with a small reduction in skeletal muscle mass (\u22120.6 kg; p = 0.035). Fasting glucose improved (p = 0.030) and HOMA-IR fell significantly. HbA1c changes were minimal, consistent with near-normal baseline values. Triglycerides decreased, while total cholesterol, LDL-C, HDL-C, liver enzymes, creatinine, uric acid, and 25-OH vitamin D remained stable. Baseline TMI (median 20.13 kg\/m3; IQR 3.80) correlated strongly with HOMA-IR (r = 0.766, p &lt; 0.001) and moderately-to-strongly with body fat percentage (r = 0.621, p &lt; 0.001). Conclusions: In this real-world cohort, Semaglutide produced rapid, clinically meaningful improvements in weight, adiposity, and insulin resistance within 3 months. Findings suggest that Semaglutide may represent a promising adjunct to lifestyle therapy in obesity management.<\/jats:p>","DOI":"10.3390\/medicines13030021","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:16:44Z","timestamp":1782699404000},"page":"21","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9682","authenticated-orcid":false,"given":"Stelu\u021ba Constan\u021ba","family":"Boroghin\u0103","sequence":"first","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"},{"name":"General Medicine Faculty, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Pediatrics, Fundeni Clinical Institute, 022318 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia-Ioana","family":"Arhire","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Papuc","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"},{"name":"Endocrinology and Diabetes, Elias Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miruna S\u00eenziana","family":"Chiper","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"},{"name":"Endocrinology and Diabetes, Elias Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana-Andreea","family":"Melu\u021b\u0103","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorana Maria","family":"P\u00eerc\u0103labu","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"},{"name":"Department of Pediatrics, Marie Curie Hospital, 077120 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Andreea","family":"D\u0103n\u0103il\u0103","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"},{"name":"Endocrinology and Diabetes, Elias Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0103d\u0103lina","family":"Cristache","sequence":"additional","affiliation":[{"name":"Kilostop Junior Nutrition Clinic, 010073 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-7318","authenticated-orcid":false,"given":"Carmen Gabriela","family":"Barbu","sequence":"additional","affiliation":[{"name":"General Medicine Faculty, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Endocrinology and Diabetes, Elias Emergency University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., and Nahata, M.C. (2024). Comparative efficacy and safety of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity or overweight: A systematic review and network meta-analysis. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070828"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Andrade, L.V.C., Cordeiro, L., de Andrade, R.C., Leandro de Ara\u00fajo, I.S., Nogueira Brasileiro, L.N., do Nascimento, A.M.B., Neme, G., Souza, S.G., Santos, C.R.P., and Franco, R.R. (2025). 12-month outcomes of GLP-1 receptor agonists in severe pediatric obesity: Real-world data. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1663499"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41390-025-04228-1","article-title":"GLP-1 receptor agonists for the treatment of obesity in children and adolescents: A meta-analysis of randomized controlled trials","volume":"99","author":"Romariz","year":"2026","journal-title":"Pediatr. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamapediatrics.2025.4291","article-title":"Prevalence of Excess Adiposity by Body Mass Index Category Among US Children and Adolescents","volume":"180","author":"Chetty","year":"2026","journal-title":"JAMA Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-World Evidence\u2014What Is It and What Can It Tell Us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"World Health Organization (2022). WHO European Regional Obesity Report 2022, WHO Regional Office for Europe."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat. Med."},{"key":"ref_8","first-page":"1194","article-title":"Efficacy and safety of GLP-1 receptor agonists in children and adolescents with obesity or type 2 diabetes: A systematic review and meta-analysis","volume":"179","author":"Setayeshgar","year":"2025","journal-title":"JAMA Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/s41366-025-01790-w","article-title":"Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis","volume":"49","author":"Yugar","year":"2025","journal-title":"Int. J. Obes."},{"key":"ref_11","first-page":"e206","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Li","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: A meta-analysis","volume":"236","author":"Ryan","year":"2021","journal-title":"J. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity (STEP TEENS)","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamapediatrics.2017.0460","article-title":"Tri-ponderal mass index vs body mass index in estimating body fat during adolescence","volume":"171","author":"Peterson","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sun, J., Yang, R., Zhao, M., Bovet, P., and Xi, B. (2021). Tri-ponderal mass index as a screening tool for identifying body fat and cardiovascular risk factors in children and adolescents: A systematic review. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.694681"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18148","DOI":"10.1038\/s41598-023-45432-5","article-title":"Associations between tri-ponderal mass index, body mass index, and high blood pressure among children and adolescents: A cross-sectional study","volume":"13","author":"Kuciene","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jada.2008.10.004","article-title":"Assessing validity and reliability of Resting Metabolic Rate in six gas analysis systems","volume":"109","author":"Cooper","year":"2009","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/archdischild-2023-326687","article-title":"Semaglutide treatment for children with obesity: An observational study","volume":"109","author":"Rahman","year":"2024","journal-title":"Arch. Dis. Child."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41366-025-01801-w","article-title":"Real -world experience with anti-obesity medications treatment in children and adolescents with overweight and obesity in Israel","volume":"49","author":"Shalitin","year":"2025","journal-title":"Int. J. Obes."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/3\/21\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:14:42Z","timestamp":1783527282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/3\/21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicines13030021"],"URL":"https:\/\/doi.org\/10.3390\/medicines13030021","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}